Advertisement

SKIP ADVERTISEMENT

You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.

Political infighting, haphazard planning and a rising anti-vaccine movement have turned the country into a cautionary tale in the coronavirus era.

A trial in São Paulo for the CoronaVac vaccine, developed by the Chinese company Sinovac Biotech. President Jair Bolsonaro has been critical of CoronaVac, instead supporting a vaccine developed by AstraZeneca and Oxford University.Credit...Victor Moriyama for The New York Times

RIO DE JANEIRO — As countries rushed their preparations to inoculate citizens against the coronavirus, Brazil, with its world-renowned immunization program and a robust pharmaceutical manufacturing capacity, should have been at a significant advantage.

But political infighting, haphazard planning and a nascent anti-vaccine movement have left the nation, which has suffered the pandemic’s second-largest death toll, without a clear vaccination program. Its citizens now have no sense of when they may get relief from a virus that has brought the public health system to its knees and crushed the economy.

“They’re playing with lives,” said Denise Garrett, a Brazilian-American epidemiologist at the Sabin Vaccine Institute, which works to expand access to vaccines. “It’s borderline criminal.”

Experts had held out hope that Brazil’s immunization prowess might allow it to handle the end of the pandemic better than it handled the beginning.

Soon after Covid-19 was first identified in the country in February, Brazil became an epicenter of the global health crisis. President Jair Bolsonaro dismissed scientific evidence, called the virus a “measly” cold that did not warrant shutting down the region’s largest economy, and berated governors who imposed quarantine measures and business closures.


Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.


Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.

Advertisement

SKIP ADVERTISEMENT